NEW YORK (GenomeWeb) – Sysmex Inostics today announced that it has signed an exclusive distribution agreement with IndivuTest for the OncoBEAM test.
Under the terms of the agreement, IndivuTest will offer Sysmex Inostics' OncoBEAM laboratory-based test throughout Germany, Austria, and Switzerland. IndivuTest will be responsible for commercial and sample logistics, while Sysmex Inostics will perform all testing services at its CLIA laboratory in Baltimore.
The OncoBEAM services analyze a wide range of clinically actionable genetic mutations in cell-free tumor DNA from blood or plasma to inform cancer treatment decisions, the firm said in a statement.
Financial details of the agreement were not disclosed.
In 2013 Japanese in vitro diagnostics firm Sysmex acquired Inostics from IndivuTest's parent company, Indivumed.